Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Kate Jin"'
Autor:
Jie Wang, Kasan Seetalarom, Yi-Long Wu, Vichien Srimuninnimit, Chong-Jen Yu, Li Zhang, Gee-Chen Chang, Virote Sriuranpong, Matt Truman, Yan Sun, Tony Mok, Guia Ladrera, Elisna Syahruddin, Benjamin Margono, Meilin Liao, Hsingjin Eugene Liu, James Chung-Man Ho, Kate Jin, Caicun Zhou, Fatima Fuerte, Sumitra Thongprasert, Ilze Bara, Hongming Pan, Johan Kurnianda, Jennifer Sandoval-Tan, Jin Soo Lee, Ashley Cheng, Yunzhong Zhu, V. Lee, Xiaoping Qian, Yuh Min Chen
Publikováno v:
The Lancet Oncology. 14:777-786
Summary Background The results of FASTACT, a randomised, placebo-controlled, phase 2 study, showed that intercalated chemotherapy and erlotinib significantly prolonged progression-free survival (PFS) in patients with advanced non-small-cell lung canc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::60dab8836abdad4cf53d126062652ba7
https://doi.org/10.1016/s1470-2045(13)70254-7
https://doi.org/10.1016/s1470-2045(13)70254-7
Autor:
Chiun Hsu, Tzeon Jye Chiou, Jennifer Sandoval-Tan, Yu-Yun Shao, Kate Jin, Chia-Tung Shun, Ann-Lii Cheng, Chih-Hung Hsu, Wu Chou Su, Yoon-Koo Kang, Tsai Shen Yang
Publikováno v:
Oncology. 85:44-52
Objectives: The bevacizumab/erlotinib combination was reported with high clinical activity for advanced hepatocellular carcinoma (HCC) by a phase II study conducted in the USA. This multicenter study across several Asian countries was to evaluate the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8bf6e23972d2d65c90205c8ab63b663
https://doi.org/10.1159/000350841
https://doi.org/10.1159/000350841
Publikováno v:
ChemInform. 23
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::09962584b76da234506beae0f84c0ad0
https://doi.org/10.1002/chin.199236145
https://doi.org/10.1002/chin.199236145
Publikováno v:
Organic Preparations and Procedures International. 24:127-133
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5109cbfcb3ebc63b90a6dfa3fd0eb37a
https://doi.org/10.1080/00304949209355685
https://doi.org/10.1080/00304949209355685
Autor:
Kate Jin, Tony Mok, Yuh Min Chen, Marina Chua-Tan, Meilin Liao, Michael Boyer, Yi-Long Wu, Michael R. Johnston, Caicun Zhou, Li Zhang, Jin Soo Lee, Winsome Chui, Aru W Sudoyo, Chong-Jen Yu, Vichien Srimuninnimit, Virote Sriuranpong, Jorge Ignacio
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(30)
Purpose This study investigated whether sequential administration of erlotinib and chemotherapy improves clinical outcomes versus chemotherapy alone in unselected, chemotherapy-naïve patients with advanced non–small-cell lung cancer (NSCLC). Patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f20cfdad7a417a2bb8b733e689a2e274
https://pubmed.ncbi.nlm.nih.gov/19738125
https://pubmed.ncbi.nlm.nih.gov/19738125
Autor:
Jorge Ignacio, Jin Soo Lee, Chong-Jen Yu, Yi-Long Wu, Li Zhang, Michael R. Johnston, Tony Mok, Yuh Min Chen, Kate Jin, Caicun Zhou
Publikováno v:
Journal of Clinical Oncology. 26:8031-8031
8031 Background: Concurrent administration of EGFR TKIs and chemotherapy in 1st line failed to improve survival. Preclinical data suggested potential antagonism due to TKI-induced G1 arrest reducin...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::51f43b27f431d63b82d705567f6f51e5
https://doi.org/10.1200/jco.2008.26.15_suppl.8031
https://doi.org/10.1200/jco.2008.26.15_suppl.8031
Autor:
Yunzhong Zhu, Kate Jin, Vichien Srimuninnimit, Jin Soo Lee, Yi-Long Wu, Chong-Jen Yu, Virote Sriuranpong, Li Zhang, Caicun Zhou, Matt Truman, Guia Ladrera, Hongming Pan, Benjamin Margono, Meilin Liao, Yan Sun, Victor C. S. Lee, Sumitra Thongprasert, Jennifer Sandoval-Tan, Yuh Min Chen, Tony Mok
Publikováno v:
ResearcherID
7519^ Background: FASTACT, a randomized, phase 2 study in advanced NSCLC, found that intercalated erlotinib with 1st-line platinum-based chemotherapy (CT) significantly prolongs progression-free survival (PFS) (HR 0.47, p=0.0002) versus CT alone (Mok
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63e0b874ca39a8fa4d64968902355c66
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000318009804295&KeyUID=WOS:000318009804295
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000318009804295&KeyUID=WOS:000318009804295
